Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,292 papers from all fields of science
Search
Sign In
Create Free Account
Metastatic Pancreatic Adenocarcinoma
An adenocarcinoma that arises from the exocrine pancreatic tissue and has metastasized to other anatomic sites.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
14 relations
Abdominal Pain
Diabetes Mellitus
Epithelial Cells
Epithelium
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Current management and future directions in metastatic pancreatic adenocarcinoma
A. Varghese
,
M. Lowery
,
K. Yu
,
E. O’Reilly
Cancer
2016
Corpus ID: 44976222
Of the anticipated 50,000 individuals expected to be diagnosed with pancreatic cancer in 2016, the majority will have metastatic…
Expand
Highly Cited
2010
Highly Cited
2010
Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma…
T. Conroy
,
F. Desseigne
,
+7 authors
A. Adenis
2010
Corpus ID: 70959416
4010 Background: In a randomized phase II trial of F vs G in 88 MPA patients (pts), we reported that F induces a response rate…
Expand
2009
2009
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens
A. Masellis
,
T. Sielaff
,
G. P. Bender
International Journal of Clinical Oncology
2009
Corpus ID: 23016143
Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the United States. Current 5-year survival is less than…
Expand
2008
2008
Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study
A. Ko
,
E. Dito
,
B. Schillinger
,
A. Venook
,
E. Bergsland
,
M. Tempero
Cancer Investigation
2008
Corpus ID: 36488544
Background: No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line…
Expand
Highly Cited
2005
Highly Cited
2005
Immunohistochemistry Can Help Distinguish Metastatic Pancreatic Adenocarcinomas From Bile Duct Adenomas and Hamartomas of the Liver
J. Hornick
,
G. Lauwers
,
R. Odze
American Journal of Surgical Pathology
2005
Corpus ID: 40437492
Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well…
Expand
Highly Cited
2004
Highly Cited
2004
A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).
E. M. O 'reilly
,
G. Abou-Alfa
,
+7 authors
S. Eckhardt
Journal of Clinical Oncology
2004
Corpus ID: 21906610
4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity…
Expand
2004
2004
Salvage Chemotherapy with Mitomycin, Docetaxel, and Irinotecan (MDI Regimen) in Metastatic Pancreatic Adenocarcinoma: A Phase I and II Trial
M. Reni
,
M. Panucci
,
+7 authors
E. Villa
Cancer Investigation
2004
Corpus ID: 45200307
Background: This study evaluates the maximum tolerated dose (MTD) and activity of mitomycin, docetaxel, and irinotecan (MDI…
Expand
2001
2001
Adenocarcinoma arising in a transplanted pancreas.
A. Roza
,
C. Johnson
,
M. Juckett
,
D. Eckels
,
M. Adams
Transplantation
2001
Corpus ID: 32255894
Tumor transmission or de novo tumor development in the transplanted organ is a rare event. Appreciation of the organ-specific…
Expand
Highly Cited
2000
Highly Cited
2000
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma
H. Ulrich‐Pur
,
G. Kornek
,
+8 authors
W. Scheithauer
Cancer
2000
Corpus ID: 23665553
Although the novel cytidine analog gemcitabine has shown superior antitumor activity compared with weekly bolus 5‐fluorouracil in…
Expand
1998
1998
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.
J. Stevenson
,
R. Scher
,
+8 authors
P. O'dwyer
European Journal of Cancer
1998
Corpus ID: 9581740
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE